Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth +22 more·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 801–900 of 1,013

  1. Cancer Immunotherapy Confers a Global Benefit
    Zahra Aryan, Mahsa Keshavarz‐Fathi, Håkan Mellstedt, Nima Rezaei · 2020 · Springer eBooks
  2. An update on novel multiple myeloma targets
    Massimo Offidani, Laura Corvatta, Sonia Morè, Valentina Maria Manieri, Attilio Olivieri · 2022 · Expert Review of Hematology
  3. Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?
    Martin Schreder, Stefan Tobias Knop · 2019 · Expert Review of Hematology
  4. Treatment outcome of newly diagnosed multiple myeloma patients: A retrospective analysis in a resource-limited setting
    Chin Sum Cheong, Tengku Ahmad Hidayat Tengku K Aziz, Nur Adila Anuar, bee chong, Edmund Fui Min Chin, Shasha Khairullah, Chee Chiat Liong, Gin Gin Gan · 2021
  5. Review of: "Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients"
    Sascha Alexander Tuchman · 2022
  6. Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses
    Meixue Duan, Doan C. Nguyen, Chester J. Joyner, Celia L. Saney, Christopher M. Tipton, Joel Andrews, Sagar Lonial, Caroline M. Kim, Ian Hentenaar, Astrid Kosters et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  7. Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM)
    Giuseppe Mele · 2024 · Preprints.org
  8. A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 Trial
    Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama et al. · 2025 · SSRN Electronic Journal
  9. Inflammatory microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma
    Wenwen Cheng, Silvia Gaggero, Lama Hasan Bou Issa, Aïcha Ouelkdite, Guillaume Escure, Adeline Cozzani, Yanick Tchantchou Njosse, Noémie Carlier, Emilie Wauquier, Gauthier Decool et al. · 2025 · medRxiv
  10. Life Beyond RVD: The Future of Induction Therapy for Multiple Myeloma
    Amrita Y. Krishnan · 2019 · Clinical Lymphoma Myeloma & Leukemia
  11. Gegen CD38 gerichtete Therapie beim multiplen Myelom
    Raphael Teipel, Christoph Röllig · 2019 · InFo Hämatologie + Onkologie
  12. The Struggle Is Real: Practice Patterns for the “Myelennial” Generation
    Nina D. Shah · 2020 · JCO Oncology Practice
  13. Non-transplant eligible multiple myeloma: deciphering optimal first line regimens
    Iuliana Vaxman, Morie Abraham Gertz · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
  14. Recent Advancements in Hematology: Knowledge, Methods and Dissemination
    Jude Fitzgibbon, Alessandro Busca, Annunziata Gloghini, Armando López‐Guillermo, Attilio Orazi, Carmelo Carlo‐Stella, Emmanuel Andrès, Eric van Breda, Fabiana Busti, Laurent Garderet et al. · 2020 · Hemato
  15. Multiples Myelom – dynamische Entwicklungen in Krankheitsverständnis und Therapie
    Torsten Steinbrunn, Stefan Tobias Knop, Hermann Einsele · 2020 · Der Onkologe
  16. Erstlinientherapie von Patienten mit multiplem Myelom
    Christoph Renner, Panagiotis Samaras · 2020 · InFo Hämatologie + Onkologie
  17. Frontline Therapy for Fit MM Patients Should Include an Antibody
    Peter Michael Voorhees · 2020 · Clinical Lymphoma Myeloma & Leukemia
  18. Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma
    Constantine S. Mitsiades · 2020 · Cold Spring Harbor Perspectives in Medicine
  19. Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
    Niels W.C.J. van de Donk, Efstathios Kastritis, Francesca Gay · 2020 · Frontiers in Oncology
  20. Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution Experience
    Danai Dima, Xiao Hu, Joshua Dower, Diana Zhang, Raymond L. Comenzo, Cindy Varga · 2021 · Research Square
  21. The Road to a Cure: Emerging Treatments for Multiple Myeloma
    Jo Caers · 2020 · Cancers
  22. Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?
    Shaji Kunnathu Kumar · 2020 · Journal of the National Comprehensive Cancer Network
  23. Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—Reply
    Smith Giri, Susan Bal, Luciano J. Costa · 2021 · JAMA Oncology
  24. Battle of the Proteasome Inhibitors: Which One Endured?
    Saad Z. Usmani · 2021 · The Hematologist
  25. Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
    Amany R. Keruakous, Silas Day, Carrie Hai-Lai Yuen · 2021 · Global Journal of Cancer Therapy
  26. The initial management of multiple myeloma in the era of novel agents: 2021 and beyond
    Omar Nadeem, Paul Gerard Guy Richardson · 2021 · British Journal of Haematology
  27. Novel investigations and treatment outcomes in systemic AL amyloidosis
    Richa Manwani · 2021 · UCL Discovery (University College London)
  28. [How I treat multiple myeloma with renal impairment].
    Weiyan Chen · 2021 · PubMed Central
  29. Monoklonális ellenanyag-alapú terápia myeloma multiplexben
    Apor Hardi, András Kozma, Andrea Ceglédi, Ágnes Tomán, András Bors, Hajnalka Andrikovics, Gábor Mikala · 2021 · Hematológia–Transzfuziológia
  30. Maintenance Strategies for Myeloma
    Ajay K. Nooka, Nisha S. Joseph · 2021 · The Cancer Journal
  31. Recent Advances in the Treatment of Multiple Myeloma
    Chiaki Nakaseko · 2020 · Nihon Naika Gakkai Zasshi
  32. Up-front ixazomib in older patients with myeloma
    Jean‐Luc Harousseau, Mohamad Mohty · 2021 · Blood
  33. Neue antikörperbasierte Therapien in der Hämatologie
    Fabian Müller · 2021 · best practice onkologie
  34. Infection in the CD38 and Anti-BCMA Era: Prevention and Treatment
    Raje Noopur · 2021 · Clinical Lymphoma Myeloma & Leukemia
  35. Quadruplets, Maintenance, and More: The Future of Therapy for Newly Diagnosed Multiple Myeloma
    Amrita Y. Krishnan · 2021 · Clinical Lymphoma Myeloma & Leukemia
  36. Recent therapeutic approaches in myeloma
    Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos · 2021 · Elsevier eBooks
  37. 人物評論の時代^[○!R] : 一九三〇年代日本のジャーナリズムにおける固有名消費
    大澤 聡 · 2011 · マス・コミュニケーション研究
  38. Multiples Myelom
    Ivana von Metzler · 2021 · Elsevier eBooks
  39. Ultra-High-Risk Group of Multiple Myeloma: A Real-World Study Based On Two Different Prognostic Evaluation Systems
    Jian‐Nan Ye, Ke-Wa Ma, Yongqin Cao · 2021 · Research Square
  40. Immunotherapeutic Strategies for Multiple Myeloma
    Jessica J. Liegel, David Avigan · 2020 · Springer eBooks
  41. Daratumumab for Immunoglobulin Light Chain Amyloidosis
    Foteini Theodorakakou, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2021 · touchREVIEWS in Oncology & Haematology
  42. Belantamab mafodotin for relapsed or refractory multiple myeloma
    Manuel David Gil‐Sierra, María Del Pilar Briceño-Casado · 2022 · Journal of Oncology Pharmacy Practice
  43. A Nine-Year-Old Male with Barth Syndrome and Cardiac Transplant Presenting with Hyperviscosity Syndrome caused by EBV-Negative Plasmacytoid PTLD
    Yixian Li, Adit L. Tal, Rachel Offenbacher · 2022
  44. Ultra-high-risk group of multiple myeloma: a real-world study based on two different prognostic evaluation systems
    Jian‐Nan Ye, Ke-Wa Ma, Yongqin Cao · 2022 · Research Square
  45. Daratumumab
    Vu Minh Hua · 2021 · Resistance to targeted anti-cancer therapeutics
  46. Multiple myeloma
    Michel Delforge · 2018 · HemaSphere
  47. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
    Jude Fitzgibbon, Sophie Park, Gordon Cook, Bruno Paiva, Annunziata Gloghini, Eric van Breda, Fabiana Busti, Laurent Garderet, Riccardo Dolcetti, Marie Robin et al. · 2020 · Hemato
  48. Comparison of Monoclonal Antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus Dexamethasone/Prednisone for the treatment of Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
    Ye Wu, Xia Wu, Xiaoyan Liu, Xue Li Zheng, Jili Deng, Yuping Gong · 2020 · Research Square
  49. Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
    2019 · Journal of the National Comprehensive Cancer Network
  50. Antibody Therapies for Multiple Myeloma
    Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos · 2021 · IntechOpen eBooks
  51. Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting
    Murielle Lalive d’Epinay, Sabine Güsewell, Nicole Graf, Ulrich Mey, Christoph Driessen, Felicitas Hitz · 2022 · Hematological Oncology
  52. Transplante autólogo de células-tronco hematopoiéticas no paciente com idade maior ou igual a 60 anos com mieloma múltiplo: avaliaçao de mortalidade, morbidade e resposta
    Marcelo Junqueira Atanazio · 2022
  53. Dysproteinemia-Associated Kidney Disease: A Single-Center Observational Study
    João Bernardo, João Pedro Oliveira, Filipe Marques, Joana Gameiro, Cristina Outerelo, Estela Nogueira, Sofia C. Jorge, José António Lopes · 2022 · Portuguese Journal of Nephrology & Hypertension
  54. Myélome multiple du sujet âgé : Entre évaluation de la fragilité des patients et progrès de l’Immunothérapie
    Thierry T.F. Facon, Salomon Manier · 2022 · Bulletin de l Académie Nationale de Médecine
  55. Ce que le cardiologue doit savoir sur le suivi d'un patient présentant un myélome multiple
    Floriane Gilles · 2022 · Annales de Cardiologie et d Angéiologie
  56. EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit
    Ajay K. Nooka, Sagar Lonial · 2022 · Clinical Lymphoma Myeloma & Leukemia
  57. Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
    Enas Yahya Mutahar · 2022 · IntechOpen eBooks
  58. Evaluación de estrategias inmunes para el control del mieloma múltiple a largo plazo
    Julio Dávila Valls · 2022
  59. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients
    Zdeněk Adam, Luděk Pour, Marta Krejčí, David Zeman, Zdeněk Řehák, Renata Koukalová, Viera Sandecká, Martin Štork, Zdeněk Král · 2022 · Onkologie
  60. Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab
    Marianna Palazzo, Gaia Ciolli, Sofia Pilerci, Irene Attucci, Ludovica Pengue, Alessandro Maria Vannucchi, Elisabetta Antonioli · 2022 · Frontiers in Hematology
  61. Plasma Cell Disorders
    Andrew Jenho Yee, Teru Hideshima, Noopur S Raje, Kenneth Carl Anderson · 2022 · Wiley eBooks
  62. Clinical, economical and ethical aspects assessing therapy outcomes in patients with multiple myelomas of high cytogenetic risk
    Yu. A. Zabolotneva, KG Gurevich · 2022 · Медицинская этика
  63. CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4
    Ľuboš Drgoňa, Lucia Masárová · 2022 · Springer eBooks
  64. Novel and Experimental Clone-Directed Therapies
    Mohamed Elemary, Ibraheem Othman · 2022 · Springer eBooks
  65. Rebooting the Myeloma Treatment Programme
    Alan E. Corcoran · 2019 · EMJ Hematology
  66. Optimizing implementation of patient-centered innovations Learning from cancer care practice
    Paul A. F. Geerts · 2022
  67. Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
    Hee Jeong Cho, Jae‐Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do et al. · 2023 · The Korean Journal of Internal Medicine
  68. Hämatologische Neoplasien und solide Tumore
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2022 · Springer eBooks
  69. Immunotherapy for Multiple Myeloma
    Anthony A. Oyekunle · 2023 · Springer eBooks
  70. Ineligible for transplant, but eligible for intensive quadruplet therapy—The value of ‘add-on’ trials for vulnerable patient populations
    Ghulam Rehman Mohyuddin, Aaron Michael Goodman · 2023 · European Journal of Cancer
  71. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  72. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  73. Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
    Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih‐Feng Cho et al. · 2023
  74. Supplementary Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
    Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih‐Feng Cho et al. · 2023
  75. Improving immunotherapeutic treatment strategies for relapsed/refractory multiple myeloma patients
    Kristine A. Frerichs · 2023
  76. Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Ângelo Maiolino, Elaine Sobral da Costa, Alberto Órfão · 2023 · Frontiers in Oncology
  77. VII. Initial Diagnosis and Treatment/Management of Multiple Myeloma in the Outpatient Setting
    Emiko Sakaida · 2022 · Nihon Naika Gakkai Zasshi
  78. The real-world outcomes of multiple myeloma treated with elotuzumab, pomalidomide, and dexamethasone
    Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito · 2023 · Research Square
  79. Acute Hypoxic Respiratory Failure Due To Lenalidomide-Induced Interstitial Pneumonitis
    Kyle O’Meara, Kush M. Fansiwala, Nikhita Kathuria‐Prakash, Monica El‐Masry, Scott Oh · 2023 · Research Square
  80. Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
    Rafaël Fonseca, Eric E. Chinaeke, Niodita Gupta‐Werner · 2023 · Mayo Clinic Proceedings Innovations Quality & Outcomes
  81. Exploring clinical and economic value of novel therapies in oncology; contemporary challenges and applications
    Mahmoud Hashim · 2023
  82. The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure
    Jose Maciel Larios, Howard R. Terebelo · 2023 · Medical Research Archives
  83. What Does an Adult Hemato-Oncology Physician Expect from a Hematopathologist?
    Fen Saj, Prasanth Ganesan · 2023 · Indian Journal of Medical and Paediatric Oncology
  84. Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation
    Pervin A. Zeynalova, О. Л. Тимофеева, Yu. E. Ryabukhina, F. M. Abbasbeyli, Купрышина Наталья Александровна, А. Г. Жуков, Timur Teimurazovich Valiev · 2023 · MD-Onco
  85. Daratumumab for the treatment of multiple myeloma
    Katrine Fladeland Iversen, Torben Plesner · 2023 · Srpski medicinski casopis Lekarske komore
  86. Daratumumab in the Treatment of Multiple Myeloma
    Aryan Marri, Jothsna Kethar · 2023 · Journal of Student Research
  87. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
    Amaia Etxebeste · 2023
  88. Use of daratumumab in combination with lenalidomide and dexamethasone (D-Rd regimen) in therapy of elderly patients with newly diagnosed multiple myeloma with high-risk cytogenetics. Clinical observation
    Yu. E. Ryabukhina, Pervin A. Zeynalova, F. M. Abbasbeyli · 2024 · MD-Onco
  89. Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?
    Salomon Manier, Thierry T.F. Facon · 2024 · Hemato
  90. Additional file 1 of Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
    Sheng Chen, Xiangrong Li, Wen Ao · 2024 · Figshare
  91. "Clinical Utility of the XF-1600 Flow Cytometer for MRD Assessment in Multiple Myeloma"
    Jordi Pétriz · 2024 · Biomedical Journal of Scientific & Technical Research
  92. Multiples Myelom
    Ivana von Metzler · 2024 · Elsevier eBooks
  93. Risk Factors Leading to Tumor Lysis Syndrome in Chemotherapy for Multiple Myeloma
    Kazuya Ishii, Atsuyoshi Okada, Yasuhiro Ue · 2023 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  94. Myeloma multiplex: a jelen kihívásai és a korszerű ellátás feltételei I.
    Zoltán Mór, Ágnes Tóth, Hussain Alizadeh, Zita Borbényi, Miklós Egyed, Árpád Illés, Tamás Masszi, Gábor Mikala · 2024 · Hematológia–Transzfuziológia
  95. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
    Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa et al. · 2024 · Annals of Hematology
  96. Forging Ahead: Quadruplet Regimens for the Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
    Alfred Chung, Anupama Deepa Kumar, Ajai Chari · 2024 · The Hematologist
  97. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
    Vânia Hungria, Anna Maria Sureda, Garcia Campelo, Marco Aurélio Salvino, Karthik Ramasamy · 2024 · Cancers
  98. Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma
    Eva-Maria Klein, Sejla Hujic, Kaya Miah · 2024 · Oncology
  99. Daratumumab-induced rhabdomyolysis in multiple myeloma: a rare case report
    Fang Luo, Yanxia Han, Qiao Ye · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
  100. Arrhythmic Stratification of Cardiac Amyloidosis
    Riccardo Scirpa, Federico Follesa, Ludovica De Fazio · 2024 · Cardiac Electrophysiology Clinics